TN-401 is being developed for the treatment of genetic arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by mutations in the PKP2 gene
Orphan Drug Designation for TN-401 is the first for a gene therapy treatment for ARVC
Expect to submit TN-401 IND application to the FDA in 2023
https://finance.yahoo.com/news/tenaya-therapeutics-receives-orphan-drug-133000411.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.